Surgery Partners (NASDAQ:SGRY) Insider Danielle Burkhalter Sells 3,469 Shares

Surgery Partners, Inc. (NASDAQ:SGRY) insider Danielle Burkhalter sold 3,469 shares of the business’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $12.83, for a total value of $44,507.27. Following the sale, the insider directly owned 76,864 shares in the company, valued at $986,165.12. This trade represents a 4.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Danielle Burkhalter also recently made the following trade(s):

• On Friday, March 6th, Danielle Burkhalter sold 7,736 shares of Surgery Partners stock. The shares were sold at an average price of $13.60, for a total value of $105,209.60.

Surgery Partners Trading Up 0.1%

Shares of SGRY opened at $12.39 on Tuesday. The business’s 50-day moving average price is $14.89 and its 200 day moving average price is $17.64. The stock has a market capitalization of $1.60 billion, a P/E ratio of -19.98 and a beta of 1.95. Surgery Partners, Inc. has a 1-year low of $12.25 and a 1-year high of $24.60. The company has a current ratio of 1.87, a quick ratio of 1.71 and a debt-to-equity ratio of 1.15.

Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings data on Monday, March 2nd. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.19). Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The firm had revenue of $885.00 million for the quarter, compared to analysts’ expectations of $866.54 million. During the same period in the prior year, the company posted $0.44 earnings per share. Surgery Partners’s quarterly revenue was up 2.4% compared to the same quarter last year. Analysts expect that Surgery Partners, Inc. will post 0.67 earnings per share for the current year.

Surgery Partners announced that its board has initiated a share buyback plan on Thursday, February 26th that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the company to reacquire up to 9.7% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Surgery Partners News Roundup

Here are the key news stories impacting Surgery Partners this week:

• Negative Sentiment: CEO Jason Eric Evans sold 20,400 shares at an average price of $12.47 for proceeds of $254,388; he still holds 920,386 shares worth about $11.48M. Form 4 CEO Sale
• Negative Sentiment: CFO David T. Doherty sold 8,867 shares at an average of $12.50 for roughly $110,838; post‑sale ownership is 221,679 shares. Form 4 CFO Sale
• Negative Sentiment: Jennifer Baldock sold 5,798 shares at $13.17 for proceeds of $76,359.66; she retains 326,474 shares. Form 4 Baldock Sale
• Negative Sentiment: Marissa Brittenham sold 3,657 shares at $12.54 for about $45,858.78; post‑sale holdings are 94,196 shares. Form 4 Brittenham Sale
• Negative Sentiment: Danielle Burkhalter sold 3,469 shares at $12.83 for about $44,507.27; she now owns 76,864 shares. Form 4 Burkhalter Sale

Institutional Trading of Surgery Partners

Institutional investors have recently made changes to their positions in the stock. Pentwater Capital Management LP grew its position in Surgery Partners by 66.9% during the third quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company’s stock valued at $252,777,000 after purchasing an additional 4,681,000 shares in the last quarter. UBS Group AG lifted its position in Surgery Partners by 111.4% in the 4th quarter. UBS Group AG now owns 7,803,974 shares of the company’s stock worth $120,571,000 after buying an additional 4,113,052 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Surgery Partners by 528.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,959,686 shares of the company’s stock valued at $30,277,000 after buying an additional 1,647,714 shares during the period. Glenview Capital Management LLC acquired a new stake in shares of Surgery Partners during the 2nd quarter valued at $33,995,000. Finally, King Street Capital Management L.P. grew its holdings in shares of Surgery Partners by 24.5% during the 2nd quarter. King Street Capital Management L.P. now owns 6,225,000 shares of the company’s stock valued at $138,382,000 after acquiring an additional 1,225,000 shares in the last quarter.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Jefferies Financial Group reaffirmed a “buy” rating on shares of Surgery Partners in a research note on Wednesday, March 4th. UBS Group reissued a “buy” rating on shares of Surgery Partners in a research note on Wednesday, March 11th. US Capital Advisors set a $21.00 target price on Surgery Partners in a report on Wednesday, March 11th. JPMorgan Chase & Co. decreased their target price on Surgery Partners from $27.00 to $20.00 and set a “neutral” rating for the company in a research report on Monday, November 24th. Finally, Benchmark reiterated a “buy” rating on shares of Surgery Partners in a report on Tuesday, March 3rd. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Surgery Partners presently has an average rating of “Moderate Buy” and a consensus price target of $23.36.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.